Heather Leitch

Current Positions

  • Coming Soon!

Research Interests

  • Coming Soon!


  1. Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM. Improved survival with iron chelation therapy for red blood cell transfusion dependent lower IPSS risk MDS may be more significant in patients with a non-RARS diagnosis. Leuk Res. 2012 Nov;36(11):1380-6.
  2. Leitch HA, Buckstein R, Shamy A, Storring JM. The immunomodulatory agents lenalidomide and thalidomide for treatment of the myelodysplastic syndromes: A clinical practice guideline. Crit Rev Oncol Hematol. 2012 Aug 14.
  3. Leitch HA, Abramson JS, Cheung MC, Hicks LK. Unanswered Questions in HIV Hematology. Adv Hematol. 2012;2012:907025.
  4. Ambler KL, Vickars LM, Leger CS, Foltz LM, Montaner JS, Harris M, Dias Lima V, Leitch HA. Clinical Features, Treatment, and Outcome of HIV-Associated Immune Thrombocytopenia in the HAART Era. Adv Hematol. 2012;2012:910954.
  5. Ezzat HM, Cheung MC, Hicks LK, Boro J, Montaner JS, Lima VD, Harris M, Leitch HA. Incidence, predictors and significance of severe toxicity in patients with human immunodeficiency virus-associated Hodgkin lymphoma. Leuk Lymphoma. 2012 Dec;53(12):2390-6.
  6. Rodrigo JA, Hicks LK, Cheung MC, Song KW, Ezzat H, Leger CS, Boro J, Montaner JS, Harris M, Leitch HA. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Adv Hematol. 2012;2012:735392. Epub 2011 Nov 14.
  7. Brahmania M, Sylwesterowic T, Leitch H. Plasmablastic lymphoma in the ano-rectal junction presenting in an immunocompetent man: a case report. J Med Case Reports. 2011 May 3;5(1):168.
  8. Leitch HA. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments. Drugs. 2011 Jan 22;71(2):155-77.


  • Coming Soon!

Comments are closed, but trackbacks and pingbacks are open.